Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/20/2005US6946441 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
09/20/2005US6946436 Oil in water emulsions; mixture containing electrolyte, polyglycerol fatty acid ester, acrylic acid-alkyl methacrylate copolymer
09/20/2005US6946297 System for stabilizing samples
09/20/2005US6946260 Allergen/inflammatory testing and diagnosis
09/20/2005US6946245 Oligonucleotides and methods for detecting hepatitis C viral nucleic acids
09/20/2005US6946244 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
09/20/2005US6946243 Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
09/20/2005US6946151 Therapeutic compositions
09/20/2005US6946149 Salt solution for colon cleansing
09/20/2005US6946146 For forming controlled release formulation of a therapeutic agent; for coating solid dosage
09/20/2005US6946141 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation
09/20/2005US6946137 Methods for the controlled delivery of pharmacologically active compounds
09/20/2005US6946125 Methods of treating West Nile virus infection
09/20/2005US6946121 Composition in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method
09/20/2005US6946120 For therapy of hair loss
09/20/2005US6946118 comprises tetracycline derivative that is poorly absorbed from the gastrointestinal tract; may include fungicide; side effect reduction; aersols; mouthwashes
09/20/2005US6946116 Amyloid plaque aggregation inhibitors and diagnostic imaging agents
09/20/2005US6946115 Especially substituted cyclic 1,3- propanyl phosphate, phosphonate and phosphoramidate esters.
09/20/2005US6945247 Method of treating cardio pulmonary diseases with no group compounds
09/20/2005CA2370692C Antitumor derivative of double dicarboxylic acid diaminoplatin complex, process for the preparing thereof, the pharmaceutical composition containing the same and application of the derivative
09/20/2005CA2360649C Method of preparing particles for agglomeration
09/20/2005CA2348869C Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
09/20/2005CA2345524C Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide
09/20/2005CA2285119C Retroviral protease inhibiting compounds
09/20/2005CA2274946C Diphenylalkyl-tetrahydropyridines, process for their preparation, and pharmaceutical compositions containing them
09/20/2005CA2258891C Anticonvulsant derivatives useful in treating psoriasis
09/20/2005CA2231535C Imidazole derivatives having affinity for alpha2 receptors activity
09/20/2005CA2218549C Method to increase retinal blood flow
09/20/2005CA2211668C Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing the same
09/20/2005CA2151604C Application of riluzole in the treatment of neurological lesions associated with traumas
09/20/2005CA2137243C Process for the production of n-.beta.-hydroxyalkyl-tri-n-carboxyalkyl -1,4,7,10-tetraazacyclododecane and n-.beta.-hydroxyalkyl-tri-n-carboxyalkyl-1,4,8,11- tetraazacyclotetradecane derivatives and their metal compllexes
09/20/2005CA2124793C Use of creatine phosphate or phosphoenolpyruvic acid for the treatment of tumours
09/20/2005CA2119757C New fluoro quinoline carboxylic-3 acid derivatives and their preparation
09/20/2005CA2113515C Inhibiting the development of tolerance to and/or dependence on an addictive substance
09/20/2005CA2084582C Process for the production of mono-n-substituted tetraaza macrocycles
09/19/2005CA2465600A1 Dosage titration for treatment of cognitive disorders
09/15/2005WO2005085957A1 Composition and process for post-etch removal of photoresist and/or sacrificial anti-reflective material deposited on a substrate
09/15/2005WO2005085294A1 Hyaluronic acid/methotrexate compound
09/15/2005WO2005085275A1 Inhibitors of hepatitis c virus ns3 protease
09/15/2005WO2005085268A2 Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
09/15/2005WO2005085267A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
09/15/2005WO2005085265A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
09/15/2005WO2005085264A1 Sulfated oligosaccharide derivatives
09/15/2005WO2005085259A2 Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines
09/15/2005WO2005085258A1 3-pyridinium methylcephem compound
09/15/2005WO2005085257A1 Macrolides and methods for producing same
09/15/2005WO2005085255A1 The extract of bulbophgllum radiatum lindl and the preparation and the use
09/15/2005WO2005085254A1 Process for inhibiting cell proliferation
09/15/2005WO2005085253A1 Pyrrolopyrimidine derivatives
09/15/2005WO2005085248A1 Heteroaryl-fused pyrazolo derivatives
09/15/2005WO2005085247A1 Crystalline forms of valacyclovir hydrochloride
09/15/2005WO2005085244A1 3,5-disubstituted 1h-pzrrolo [2,3-b] pyridines as jnk inhibitors
09/15/2005WO2005085242A1 Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
09/15/2005WO2005085241A1 Thiazole derivative
09/15/2005WO2005085240A2 Process for the preparation of ziprasidone
09/15/2005WO2005085237A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
09/15/2005WO2005085228A1 Cycloalkanopyridine derivative
09/15/2005WO2005085223A1 Composition for prevention and/or treatment of bone disease, functional food or health food containing the composition, and medicinal preparation containing the composition as active ingredient
09/15/2005WO2005085218A1 A novel process for preparing valdecoxib
09/15/2005WO2005085215A1 Anticancer agent
09/15/2005WO2005085214A1 Diaryl-substituted five-membered heterocycle derivative
09/15/2005WO2005085213A1 Compounds derived from 4­-anilinequinazolines with adenosine-kiase inhibitor properties
09/15/2005WO2005085212A1 Substituted pyrimidine derivative
09/15/2005WO2005085210A1 Nitriles and medicinal compositions containing the same as the active ingredient
09/15/2005WO2005085209A1 Basic amine compound and use thereof
09/15/2005WO2005085202A1 Pyridinamide derivative as kinase inhibitors
09/15/2005WO2005085201A1 Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
09/15/2005WO2005085200A1 Pyridone derivative
09/15/2005WO2005085196A2 Inhibitors of dna methylation in tumor cells
09/15/2005WO2005085195A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
09/15/2005WO2005085182A1 Dl-hydroxybenzenamides having anticonvulsive activity
09/15/2005WO2005085179A1 Amino acid derivatives
09/15/2005WO2005084754A2 Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation
09/15/2005WO2005084727A1 Bone grafting material, comprising a porous carrier and at least one pyrrolindone, a method for its production and an implant
09/15/2005WO2005084713A2 Enzyme-prodrug therapy for prosthetic joint repair
09/15/2005WO2005084712A2 Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
09/15/2005WO2005084710A2 Nanocell drug delivery system
09/15/2005WO2005084709A1 Remedy for urinary disorder
09/15/2005WO2005084708A1 Medicinal composition containing cxcr3 inhibitor
09/15/2005WO2005084707A1 Method of utilizing organic cation transporter oct3-related molecule for treating mental diseases such as depression, anxiety neurosis, drug addiction and the like
09/15/2005WO2005084704A1 Digestive bypass composition for arthropod and uses thereof
09/15/2005WO2005084697A1 Regulator for adiponectin receptor expression
09/15/2005WO2005084695A2 Use of carboxypeptidase g for combating antifolate toxicity
09/15/2005WO2005084692A2 Effect of beta-glucan on stem cell recruitment and tissue repair
09/15/2005WO2005084689A1 Radix astragli extract and production method and use thereof
09/15/2005WO2005084688A1 An injection power containing vermifuge
09/15/2005WO2005084687A2 Boronic acid thrombin inhibitors
09/15/2005WO2005084686A2 Boronate medicaments for preventing thrombosis during surgery
09/15/2005WO2005084685A2 Boronate medicaments suitable for short duration anticoagulation
09/15/2005WO2005084684A1 Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro
09/15/2005WO2005084683A1 Vegetable lecithin-based composition, ex of soy, complex b vitamins, and acetylsalicylic acid and the use thereof for producing a drug for treating neurodegenerative diseases
09/15/2005WO2005084682A1 Pharmaceutical composition comprising cyclodextrin complex of tibolone
09/15/2005WO2005084681A1 Composition for increasing levels of hormones and a method for preparation of said composition
09/15/2005WO2005084680A1 Synergistic anti-inflammatory pharmaceutical compositions and methods of use
09/15/2005WO2005084679A1 Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
09/15/2005WO2005084678A1 Alkaloid formulations
09/15/2005WO2005084677A1 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies
09/15/2005WO2005084676A1 Pharmaceutical preparation containing tolperisone with controlled release of active substances for oral administration
09/15/2005WO2005084675A1 Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency
09/15/2005WO2005084674A1 Amorphous form of desloratadine and a process for the preparation thereof
1 ... 4538 4539 4540 4541 4542 4543 4544 4545 4546 4547 4548 4549 4550 4551 4552 4553 4554 4555 4556 4557 4558 ... 7860